GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Clinical Trials
729
Trial Phases
5 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (681 trials with phase data)• Click on a phase to view related trials
Study of GS-5319 in Adults With Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: GS-5319
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 178
- Registration Number
- NCT07128303
- Locations
- 🇺🇸
START San Antonio, San Antonio, Texas, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
Study of GS-1219 in Participants With HIV-1
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 4
- Registration Number
- NCT07115368
- Locations
- 🇺🇸
Ruane Clinical Research Group, Los Angeles, California, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
- Conditions
- Chronic Hepatitis Delta
- Interventions
- Drug: GS-4321Drug: GS-4321 Placebo
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT07096193
- Locations
- 🇺🇸
Investigative Site, Anaheim, California, United States
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
- Conditions
- HIV-1-infection
- Interventions
- Drug: B/F/TAF
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT07055451
- Locations
- 🇺🇸
Grady Health System - Ponce de Leon Center, Atlanta, Georgia, United States
🇿🇦Family Centre for Research with Ubuntu (FAMCRU), Cape Town, South Africa
🇿🇦WITS RHI Shandukani Research Centre, Johannesburg, South Africa
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
- Conditions
- HIV Pre-exposure Prophylaxis
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT07047716
- Locations
- 🇺🇸
Yale University; School of Medicine; AIDS Program, New Haven, Connecticut, United States
🇺🇸Fenway Health, Boston, Massachusetts, United States
🇺🇸NC TraCS Institute - CTRC, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 132
- Next
News
South Africa Approves Groundbreaking Twice-Yearly HIV Prevention Injection Lenacapavir
South Africa becomes the first African nation to approve lenacapavir, a revolutionary HIV prevention injection that provides six months of protection per dose, marking a significant advancement in HIV prevention strategies.
Gilead Presents Three-Year Livdelzi Data Showing Liver Health Stabilization in Primary Biliary Cholangitis Patients
Gilead will present new three-year interim data from the ASSURE study demonstrating that Livdelzi (seladelpar) may help stabilize or improve liver health in patients with primary biliary cholangitis.
Dublin Biotech Meta-Flux Raises €1.8M to Enhance Drug Development Accuracy with AI Platform
Dublin-based biotech Meta-Flux has secured €1.8 million in seed funding from senior executives at Pfizer, Merck, and Gilead Sciences to expand its AI-powered drug development platform.
Nurix Therapeutics Advances Bexobrutideg Toward Pivotal CLL Trials with Strong Phase 1 Data
Nurix Therapeutics announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia patients in the second half of 2025, including both accelerated approval and confirmatory Phase 3 studies.
Expedition Therapeutics Secures $165 Million Series A to Advance First-in-Class DPP1 Inhibitor for COPD
Expedition Therapeutics closed an oversubscribed $165 million Series A financing co-led by Sofinnova Investments and Novo Holdings to advance EXPD-101, a next-generation DPP1 inhibitor targeting neutrophilic inflammation in COPD.
Cartography Biosciences Raises $67M Series B to Advance Novel T-Cell Engager for Colorectal Cancer
Cartography Biosciences secured $67 million in Series B funding led by Pfizer Ventures to advance its lead T-cell engager CBI-1214 targeting colorectal cancer into Phase 1 trials.
Gilead Sciences Secures Exclusive Global Rights to First-in-Class P-Glycoprotein Inhibitor Encequidar
Health Hope Pharma and Hanmi Pharm have granted Gilead Sciences exclusive global licensing rights to encequidar, a first-in-class P-glycoprotein inhibitor, specifically for virology applications.
Lupin Receives Tentative FDA Approval for Generic HIV Treatment Targeting $16.2 Billion Market
Lupin Limited has received tentative FDA approval for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, targeting a significant HIV treatment market.
Zimbabwe Selected for Global Rollout of Lenacapavir, Breakthrough Twice-Yearly HIV Prevention Drug
Zimbabwe has been chosen as one of only ten countries worldwide to introduce lenacapavir, a groundbreaking HIV prevention drug developed by Gilead Sciences that requires only twice-yearly injections.
Nurix and Gilead's IRAK4 Degrader GS-6791 Shows Promise for Inflammatory Skin Diseases in Preclinical Studies
Nurix Therapeutics presented preclinical data for GS-6791, a novel IRAK4 protein degrader developed in collaboration with Gilead Sciences, demonstrating potent inhibition of IL-1 and IL-36 inflammatory pathways.